SCHEMBL2665063

SCHEMBL2665063

CC1CCCC(C)N1S(=O)(=O)c1cnc(NC(=O)N(C2CCCCC2)[C@H]2CC[C@H](C)CC2)s1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
ALDH1A1 P00352 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MAPT P10636 2/20 0.33
MAPK1 P28482 1/20 0.33
NAMPT P43490 1/20 0.33
ACHE P22303 3/20 0.33
GAA P10253 2/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
HTT P42858 2/20 0.32
PSEN1 P49768 1/20 0.32
PSEN2 P49810 1/20 0.32
APH1B Q8WW43 1/20 0.32
NCSTN Q92542 1/20 0.32
APH1A Q96BI3 1/20 0.32
PSENEN Q9NZ42 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2649466 1.00 POLB (0.37) POLBMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL2649468 1.00 POLB (0.37) POLBMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL2648362 0.88 ALDH1A1 (0.39) POLBMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL2648366 0.88 ALDH1A1 (0.39) POLBMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL2647782 0.86 SMN1; SMN2 (0.38) MEN1KMT2ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL2647778 0.86 SMN1; SMN2 (0.38) MEN1KMT2ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL2647765 0.85 SMN1; SMN2 (0.37) MEN1KMT2ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL2647767 0.85 SMN1; SMN2 (0.37) MEN1KMT2ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL2648989 0.84 POLB (0.44) POLBSMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL2648532 0.84 POLB (0.44) POLBSMN1; SMN2ALDH1A1L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582769-B2 Dicycloalkyl urea glucokinase activators NOVO NORDISK A/S (DK) 2009-09-01 US disclosed
US-7582769-B2 Dicycloalkyl urea glucokinase activators NOVO NORDISK A/S (DK) 2009-09-01 US disclosed
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2009-05-07 US disclosed
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2009-05-07 US disclosed
WO-2007006760-A1 DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators GCK, GCKR, UCK2 POLB 3011/4885MEN1 4339/4885KMT2A 2732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.